PMID- 32553077
OWN - NLM
STAT- MEDLINE
DCOM- 20200928
LR  - 20220415
IS  - 2214-0190 (Electronic)
IS  - 0895-3988 (Linking)
VI  - 33
IP  - 5
DP  - 2020 May 20
TI  - Hyperbaric Oxygen Treatment Improves Hearing Level via Attenuating TLR4/NF-kappaB 
      Mediated Inflammation in Sudden Sensorineural Hearing Loss Patients.
PG  - 331-337
LID - 10.3967/bes2020.045 [doi]
AB  - OBJECTIVE: Hyperbaric oxygen treatment (HBOT) has demonstrated efficacy in 
      improving hearing levels of patients with idiopathic sudden sensorineural hearing 
      loss (ISSHL); however, the underlying mechanisms are not well understood. HBOT 
      alleviates the inflammatory response, which is mediated by Toll-like receptor 
      (TLR) 4 and nuclear factor (NF)-kappaB. In this study we investigated whether HBOT 
      attenuates inflammation in ISHHL patients via alteration of TLR4 and NF-kappaB 
      expression. METHODS: ISHHL patients ( n = 120) and healthy control subjects ( n = 
      20) were enrolled in this study. Patients were randomly divided into medicine 
      group treated with medicine only ( n = 60) and HBO group receiving both HBOT and 
      medicine ( n = 60). Audiometric testing was performed pre- and post-treatment. 
      TLR4, NF-small ka, CyrillicB, and TNF-alpha expression in peripheral blood of ISSHL patients and 
      healthy control subjects was assessed by ELISA before and after treatment. 
      RESULTS: TLR4, NF-kappaB, and TNF-alpha levels were upregulated in ISSHL patients 
      relative to healthy control subjects; the levels were decreased following 
      treatment and were lower in the HBO group than that in the medicine group 
      post-treatment ( P < 0.05 and P < 0.01). CONCLUSION: HBOT alleviates hearing loss 
      in ISSHL patients by suppressing the inflammatory response induced by TLR4 and 
      NF-kappaB signaling.
CI  - Copyright (c) 2020 The Editorial Board of Biomedical and Environmental Sciences. 
      Published by China CDC. All rights reserved.
FAU - Liu, Xue Hua
AU  - Liu XH
AD  - Department of Hyperbaric Oxygen Medicine, Beijing Chaoyang Hospital, Capital 
      Medical University, Beijing 100020, China.
FAU - Liang, Fang
AU  - Liang F
AD  - Department of Hyperbaric Oxygen Medicine, Beijing Chaoyang Hospital, Capital 
      Medical University, Beijing 100020, China.
FAU - Jia, Xing Yuan
AU  - Jia XY
AD  - Institute of Basic Medicine Sciences, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing 100020, China.
FAU - Zhao, Lin
AU  - Zhao L
AD  - Department of Hyperbaric Oxygen Medicine, Beijing Pinggu Hospital, Beijing 
      101200, China.
FAU - Zhou, Yan
AU  - Zhou Y
AD  - Institute of Basic Medicine Sciences, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing 100020, China.
FAU - Yang, Jing
AU  - Yang J
AD  - Department of Hyperbaric Oxygen Medicine, Beijing Chaoyang Hospital, Capital 
      Medical University, Beijing 100020, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Biomed Environ Sci
JT  - Biomedical and environmental sciences : BES
JID - 8909524
RN  - 0 (NF-kappa B p50 Subunit)
RN  - 0 (NFKB1 protein, human)
RN  - 0 (TLR4 protein, human)
RN  - 0 (Toll-Like Receptor 4)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - China
MH  - Female
MH  - Hearing Loss, Sensorineural/*therapy
MH  - Hearing Loss, Sudden/*therapy
MH  - Humans
MH  - *Hyperbaric Oxygenation
MH  - Inflammation/genetics/*therapy
MH  - Male
MH  - Middle Aged
MH  - NF-kappa B p50 Subunit/*genetics/metabolism
MH  - Toll-Like Receptor 4/*genetics/metabolism
MH  - Young Adult
OTO - NOTNLM
OT  - Hyperbaric oxygen treatment
OT  - Nuclear factor-kB
OT  - Sudden sensorineural hearing loss
OT  - Toll-like receptor 4
EDAT- 2020/06/20 06:00
MHDA- 2020/09/29 06:00
CRDT- 2020/06/20 06:00
PHST- 2019/07/30 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/06/20 06:00 [entrez]
PHST- 2020/06/20 06:00 [pubmed]
PHST- 2020/09/29 06:00 [medline]
AID - 10.3967/bes2020.045 [doi]
PST - ppublish
SO  - Biomed Environ Sci. 2020 May 20;33(5):331-337. doi: 10.3967/bes2020.045.